Monitoring the response of the tumor cells to TGF-β1 by analyzing the phosphorylation status of Smad2 demonstrated an increased phosphorylation status of Smad2 upon TGF-β1 treatment, but the overall amount of protein remained the same in all RCC cell lines tested (Figure 2B). The gene discussed is SMAD2; the disease is neoplasm.